Gynecologic oncology reports · 2025
Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jang Minyoung, Gysler Stefan, Latif Nawar A, Ko Emily M, Giuntoli Robert L, Kim Sarah H, Simpkins Fiona, Nasioudis Dimitrios
Аннотация
OBJECTIVE: Mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. While prognosis of early stage disease is excellent, novel treatment options are needed for advanced stage and recurrent MOC, which are associated with poor oncologic outcomes. In this context, we aimed to investigate the genomic profile of MOC and characterize the prevalence of actionable genomic alterations.
METHODS: The American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange was accessed, and patients with mucinous ovarian, appendiceal and colorectal carcinoma were identified. Data from the OncoKB database, as provided by cBioPortal, were utilized to determine the presence of pathogenic gene alterations. When comparing the genomic profile of mucinous ovarian and colorectal or appendiceal carcinoma, to decrease the false discovery rate, a q-value of < 0.05 as derived from the Benjamini-Hochberg FDR correction procedure was deemed statistically significant.
RESULTS: A total of 148 patients with MOC contributing to 157 tumor samples were identified. The most commonly observed genetic alterations were in KRAS (69.4 %), TP53 (64.3 %), CDKN2A (33.3 %), CDKN2B (24 %), ERBB2 (12 %), PIK3CA (9.6 %), and ARID1A (9.0 %). BRCA1 (0 %) and BRCA2 (2.3 %) mutations were rare. Homologous deletion of chromosome 9p21.3 was present in 34.4 % of patients. Compared to mucinous appendiceal carcinoma (n = 268), MOC is characterized by a higher incidence of TP53, CDKN2A, CDKN2B, and ERBB2 and a lower rate of GNAS gene alterations (q < 0.001). Compared to colorectal mucinous adenocarcinoma (n = 358), MOC is characterized by a higher incidence of KRAS, TP53, CDKN2A, CDKN2B, and ERBB2 and a lower rate of PIK3CA, KMT2D, SMAD4, BRAF, and APC gene alterations (q < 0.001).
CONCLUSIONS: MOC has a distinct genomic profile with molecular vulnerabilities that can be exploited using novel targeted therapies. Participation of patients with MOC in molecularly driven early phase basket trials should be encouraged.
METHODS: The American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange was accessed, and patients with mucinous ovarian, appendiceal and colorectal carcinoma were identified. Data from the OncoKB database, as provided by cBioPortal, were utilized to determine the presence of pathogenic gene alterations. When comparing the genomic profile of mucinous ovarian and colorectal or appendiceal carcinoma, to decrease the false discovery rate, a q-value of < 0.05 as derived from the Benjamini-Hochberg FDR correction procedure was deemed statistically significant.
RESULTS: A total of 148 patients with MOC contributing to 157 tumor samples were identified. The most commonly observed genetic alterations were in KRAS (69.4 %), TP53 (64.3 %), CDKN2A (33.3 %), CDKN2B (24 %), ERBB2 (12 %), PIK3CA (9.6 %), and ARID1A (9.0 %). BRCA1 (0 %) and BRCA2 (2.3 %) mutations were rare. Homologous deletion of chromosome 9p21.3 was present in 34.4 % of patients. Compared to mucinous appendiceal carcinoma (n = 268), MOC is characterized by a higher incidence of TP53, CDKN2A, CDKN2B, and ERBB2 and a lower rate of GNAS gene alterations (q < 0.001). Compared to colorectal mucinous adenocarcinoma (n = 358), MOC is characterized by a higher incidence of KRAS, TP53, CDKN2A, CDKN2B, and ERBB2 and a lower rate of PIK3CA, KMT2D, SMAD4, BRAF, and APC gene alterations (q < 0.001).
CONCLUSIONS: MOC has a distinct genomic profile with molecular vulnerabilities that can be exploited using novel targeted therapies. Participation of patients with MOC in molecularly driven early phase basket trials should be encouraged.